HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Proglumide treatment in bile-induced acute experimental pancreatitis.

Abstract
Rats with acute experimental pancreatitis were treated with the cholecystokinin (CCK)-receptor antagonist proglumide. S-amylase was not affected by proglumide during the initial 4 h but was reduced after 72 h as compared to pre-pancreatitis values. The amylase levels in peritoneal fluid were lower in proglumide treated animals at 1, 2, 4 and 72 h after the induction of the pancreatitis, and amylase in pancreatic tissue was increased by proglumide after six but not 72 h. In spite of these biochemical changes, suggesting beneficial therapeutic effects by proglumide, survival rate was not improved when using a dose of 100 mg/kg every 8 h for 48 h and significantly reduced at a dose of 500 mg/kg every 8 h for 48 h. The results do not support proglumide as the sole treatment in acute pancreatitis.
AuthorsE Tarpila, L Larsson, I Lilja, I Ihse
JournalInternational journal of pancreatology : official journal of the International Association of Pancreatology (Int J Pancreatol) Vol. 3 Issue 2-3 Pg. 195-202 (Mar 1988) ISSN: 0169-4197 [Print] United States
PMID2452222 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Glutamine
  • Amylases
  • Proglumide
Topics
  • Acute Disease
  • Amylases (metabolism)
  • Animals
  • Bile
  • Glutamine (analogs & derivatives)
  • Male
  • Pancreatitis (drug therapy, etiology)
  • Proglumide (therapeutic use)
  • Rats
  • Rats, Inbred Strains

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: